Antisense oligonucleotides (ASOs) have emerged as one of the most advanced therapeutic strategies for ALS, particularly in genetically defined subtypes such as SOD1- and C9orf72-associated ALS. This evidence concerns the gene C9orf72 and amyotrophic lateral sclerosis.